Medifast Future Growth

Future criteria checks 1/6

Medifast's revenue is forecast to decline at 13.4% per annum while its annual earnings are expected to grow at 4.4% per year. EPS is expected to grow by 5% per annum. Return on equity is forecast to be 2.2% in 3 years.

Key information

4.4%

Earnings growth rate

5.0%

EPS growth rate

Personal Products earnings growth26.1%
Revenue growth rate-13.4%
Future return on equity2.2%
Analyst coverage

Low

Last updated05 Nov 2024

Recent future growth updates

Recent updates

Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued

Nov 06

Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation

Sep 03

Medifast Business Continues To Shrink, Stock Still Risky

Aug 27

Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing

Jun 26

Medifast: Significant Undervaluation Even As Struggles Persist

May 24

At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

May 24
At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop

May 24
Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop

Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

May 06
Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

May 01
The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

Medifast: Cheap Valuation, Uncertain Future

Mar 20

Medifast Is Getting Attractive

Mar 07

Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Feb 22
Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Medifast Share Price Loses Weight, But Is There Still Value To Be Had?

Jan 20

Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Dec 09
Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome

Nov 24

Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Nov 21
Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Medifast: Unveiling A Challenge Beyond Weight Loss Drugs

Nov 09

Medifast: The Race To Weight-Loss Drugs Not Lost Yet

Oct 09

Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs

Aug 04

Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

Jul 26
Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

In The Murky MLM Space, Medifast Might Actually Hold Some Promise

Jul 21

Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Jul 05
Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Medifast: In Survival Mode Against Diet Pills And The Recession

Jun 14

Medifast Holds Value During Headwinds

May 28

Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M

Feb 21

Medifast: A Low Earnings Multiple Despite Strong Financial Performance

Feb 07

At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Jan 19
At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Medifast declares $1.64 dividend

Dec 08

A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Dec 01
A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Nov 10
Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems

One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates

Nov 08
One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates

Medifast: This High-Yield Blue Chip Dividend Stock Is A Strong Buy

Nov 06

What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

Oct 20
What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt

Sep 18
We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt

Medifast declares $1.64 dividend

Sep 08

Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?

Sep 02
Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?

Medifast: Let's Dive Into Its Q2 Earnings And Assess The Bad And The Good

Aug 21

Earnings and Revenue Growth Forecasts

NYSE:MED - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026509520271
12/31/2025510318232
12/31/2024598027352
9/30/202467473440N/A
6/30/2024770295461N/A
3/31/2024898688591N/A
12/31/20231,07299141148N/A
9/30/20231,218120174189N/A
6/30/20231,373133200214N/A
3/31/20231,530142199215N/A
12/31/20221,599144178195N/A
9/30/20221,639151116135N/A
6/30/20221,6621576896N/A
3/31/20221,6031654073N/A
12/31/20211,5261646095N/A
9/30/20211,41315897122N/A
6/30/20211,271150130147N/A
3/31/20211,097125174184N/A
12/31/2020935103139145N/A
9/30/202084195140145N/A
6/30/202075976118121N/A
3/31/2020726767278N/A
12/31/2019714787484N/A
9/30/2019689747080N/A
6/30/2019638726069N/A
3/31/2019568646776N/A
12/31/2018501565661N/A
9/30/2018433475155N/A
6/30/201837140N/A61N/A
3/31/201833034N/A55N/A
12/31/201730228N/A43N/A
9/30/201728625N/A33N/A
6/30/201727724N/A27N/A
3/31/201727320N/A24N/A
12/31/201627518N/A25N/A
9/30/201627318N/A28N/A
6/30/201627117N/A30N/A
3/31/201627219N/A27N/A
12/31/201527320N/A29N/A
9/30/201527418N/A28N/A
6/30/201527718N/A27N/A
3/31/201527919N/A25N/A
12/31/201428521N/A26N/A
9/30/201426727N/A33N/A
6/30/201428527N/A31N/A
3/31/201430728N/A38N/A
12/31/201332427N/A42N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MED's forecast earnings growth (4.4% per year) is above the savings rate (2.6%).

Earnings vs Market: MED's earnings (4.4% per year) are forecast to grow slower than the US market (15.4% per year).

High Growth Earnings: MED's earnings are forecast to grow, but not significantly.

Revenue vs Market: MED's revenue is expected to decline over the next 3 years (-13.4% per year).

High Growth Revenue: MED's revenue is forecast to decline over the next 3 years (-13.4% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MED's Return on Equity is forecast to be low in 3 years time (2.2%).


Discover growth companies